Sfoglia per Autore
A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis
2017-01-01 Angioni, Maria Maddalena; Bellofatto, Kevin; Merlin, Simone; Menegon, Silvia; Perra, Andrea; Petrelli, Annalisa; Sulas, Pia; Giordano, Silvia; Columbano, Amedeo; Follenzi, Antonia
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival
2016-01-01 Mattu, Sandra; Fornari, Francesca; Quagliata, Luca; Perra, Andrea; Angioni, Maria Maddalena; Petrelli, Annalisa; Menegon, Silvia; Morandi, Andrea; Chiarugi, Paola; Ledda-Columbano, Giovanna Maria; Gramantieri, Laura; Terracciano, Luigi; Giordano, Silvia; Columbano, Amedeo
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis
2016-01-01 Kowalik, Marta Anna; Guzzo, Giulia; Morandi, Andrea; Perra, Andrea; Menegon, Silvia; Masgras, Ionica; Trevisan, Elena; Angioni, Maria Maddalena; Fornari, Francesca; Quagliata, Luca; Ledda-Columbano, Giovanna Maria; Gramantieri, Laura; Terracciano, Luigi; Giordano, Silvia; Chiarugi, Paola; Rasola, Andrea; Columbano, Amedeo
Istologia Medica
2016-01-01 Saverio Cinti, Michelangelo Cordenonsi, Simona Corso, Ottavio Cremona, Massimo De Felici, Roberta Di Pietro, Nicoletta Gagliano, Silvia Giordano, Nadir M. Maraldi, Carla Martinelli, Alessandro Moretta, Sergio Morini, Beatrice Nico, Maria Prat, Domenico Ruzzolo, Domenico Ribatti, Giovanni Francesco Spatola, Carlo Tacchetti
The Dual Roles of NRF2 in Cancer
2016-01-01 Menegon, Silvia; Columbano, Amedeo; Giordano, Silvia
How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
2016-01-01 Corso, Simona; Giordano, Silvia
MiRs*: Innocent bystanders only?
2016-01-01 Giordano, Silvia
Growth Factor Receptors
2015-01-01 Silvia Giordano, Carla Boccaccio, Paolo M. Comoglio
By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.
2015-01-01 Petrelli, A; Carollo, R; Cargnelutti, M; Iovino, F; Callari, M; Cimino, D; Todaro, M; Mangiapane, Lr; Giammona, A; Cordova, A; Montemurro, F; Taverna, D; Daidone, Mg; Stassi, G; Giordano, S.
Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis.
2015-01-01 Zavattari P;Perra A;Menegon S;Kowalik MA;Petrelli A;Angioni MM;Follenzi A;Quagliata L;Ledda-Columbano GM;Terracciano L;Giordano S;Columbano A
Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis
2015-01-01 Kowalik, Marta Anna; Sulas, Pia; Ledda-Columbano, Giovanna Maria; Giordano, Silvia; Columbano, Amedeo; Perra, Andrea
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC.
2014-01-01 Frau C;Loi R;Petrelli A;Perra A;Menegon S;Kowalik MA;Pinna S;Leoni VP;Fornari F;Gramantieri L;Ledda-Columbano GM;Giordano S;Columbano A
Activation of RAS family members confers resistance to ROS1 targeting drugs.
2014-01-01 Cargnelutti M;Corso S;Pergolizzi M;Mévellec L;Aisner DL;Dziadziuszko R;Varella-Garcia M;Comoglio PM;Doebele RC;Vialard J;Giordano S
Targeted therapies in cancer and mechanisms of resistance.
2014-01-01 Corso S;Giordano S
MicroRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC.
2014-01-01 Petrelli A;Perra A;Cora D;Sulas P;Menegon S;Manca C;Migliore C;Kowalik MA;Ledda-Columbano GM;Giordano S;Columbano A
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.
2014-01-01 Martin V;Corso S;Comoglio PM;Giordano S
YAP activation is an early event and a potential therapeutic target in liver cancer development.
2014-01-01 Perra A;Kowalik MA;Ghiso E;Ledda-Columbano GM;Di Tommaso L;Angioni MM;Raschioni C;Testore E;Roncalli M;Giordano S;Columbano A
Targeting MET: why, where and how?
2013-01-01 Ghiso E;Giordano S
Met as a therapeutic target in HCC: Facts and hopes.
2013-01-01 Giordano S; Columbano A.
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer.
2013-01-01 Bardelli A*;Corso S*;Bertotti A*;Hobor S;Valtorta E;Siravegna G;Sartore-Bianchi A;Scala E;Cassingena A;Zecchin D;Apicella M;Migliardi G;Galimi F;Lauricella C;Zanon C;Perera T;Veronese S;Corti G;Amatu A;Gambacorta M;Diaz LA Jr;Sausen M;Velculescu VE;Comoglio P;Trusolino L;Di Nicolantonio F;Giordano S;Siena S (*Co-First Authors)
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis | 2017 | Angioni, Maria Maddalena; Bellofatto, Kevin; Merlin, Simone; Menegon, Silvia; Perra, Andrea; Petrelli, Annalisa; Sulas, Pia; Giordano, Silvia; Columbano, Amedeo; Follenzi, Antonia | |
| The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival | 2016 | Mattu, Sandra; Fornari, Francesca; Quagliata, Luca; Perra, Andrea; Angioni, Maria Maddalena; Petrelli, Annalisa; Menegon, Silvia; Morandi, Andrea; Chiarugi, Paola; Ledda-Columbano, Giovanna Maria; Gramantieri, Laura; Terracciano, Luigi; Giordano, Silvia; Columbano, Amedeo | |
| Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis | 2016 | Kowalik, Marta Anna; Guzzo, Giulia; Morandi, Andrea; Perra, Andrea; Menegon, Silvia; Masgras, Ionica; Trevisan, Elena; Angioni, Maria Maddalena; Fornari, Francesca; Quagliata, Luca; Ledda-Columbano, Giovanna Maria; Gramantieri, Laura; Terracciano, Luigi; Giordano, Silvia; Chiarugi, Paola; Rasola, Andrea; Columbano, Amedeo | |
| Istologia Medica | 2016 | Saverio Cinti, Michelangelo Cordenonsi, Simona Corso, Ottavio Cremona, Massimo De Felici, Roberta Di Pietro, Nicoletta Gagliano, Silvia Giordano, Nadir M. Maraldi, Carla Martinelli, Alessandro Moretta, Sergio Morini, Beatrice Nico, Maria Prat, Domenico Ruzzolo, Domenico Ribatti, Giovanni Francesco Spatola, Carlo Tacchetti | |
| The Dual Roles of NRF2 in Cancer | 2016 | Menegon, Silvia; Columbano, Amedeo; Giordano, Silvia | |
| How Can Gastric Cancer Molecular Profiling Guide Future Therapies? | 2016 | Corso, Simona; Giordano, Silvia | |
| MiRs*: Innocent bystanders only? | 2016 | Giordano, Silvia | |
| Growth Factor Receptors | 2015 | Silvia Giordano, Carla Boccaccio, Paolo M. Comoglio | |
| By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. | 2015 | Petrelli, A; Carollo, R; Cargnelutti, M; Iovino, F; Callari, M; Cimino, D; Todaro, M; Mangiapane, Lr; Giammona, A; Cordova, A; Montemurro, F; Taverna, D; Daidone, Mg; Stassi, G; Giordano, S. | |
| Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. | 2015 | Zavattari P;Perra A;Menegon S;Kowalik MA;Petrelli A;Angioni MM;Follenzi A;Quagliata L;Ledda-Columbano GM;Terracciano L;Giordano S;Columbano A | |
| Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis | 2015 | Kowalik, Marta Anna; Sulas, Pia; Ledda-Columbano, Giovanna Maria; Giordano, Silvia; Columbano, Amedeo; Perra, Andrea | |
| Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC. | 2014 | Frau C;Loi R;Petrelli A;Perra A;Menegon S;Kowalik MA;Pinna S;Leoni VP;Fornari F;Gramantieri L;Ledda-Columbano GM;Giordano S;Columbano A | |
| Activation of RAS family members confers resistance to ROS1 targeting drugs. | 2014 | Cargnelutti M;Corso S;Pergolizzi M;Mévellec L;Aisner DL;Dziadziuszko R;Varella-Garcia M;Comoglio PM;Doebele RC;Vialard J;Giordano S | |
| Targeted therapies in cancer and mechanisms of resistance. | 2014 | Corso S;Giordano S | |
| MicroRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC. | 2014 | Petrelli A;Perra A;Cora D;Sulas P;Menegon S;Manca C;Migliore C;Kowalik MA;Ledda-Columbano GM;Giordano S;Columbano A | |
| Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. | 2014 | Martin V;Corso S;Comoglio PM;Giordano S | |
| YAP activation is an early event and a potential therapeutic target in liver cancer development. | 2014 | Perra A;Kowalik MA;Ghiso E;Ledda-Columbano GM;Di Tommaso L;Angioni MM;Raschioni C;Testore E;Roncalli M;Giordano S;Columbano A | |
| Targeting MET: why, where and how? | 2013 | Ghiso E;Giordano S | |
| Met as a therapeutic target in HCC: Facts and hopes. | 2013 | Giordano S; Columbano A. | |
| Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. | 2013 | Bardelli A*;Corso S*;Bertotti A*;Hobor S;Valtorta E;Siravegna G;Sartore-Bianchi A;Scala E;Cassingena A;Zecchin D;Apicella M;Migliardi G;Galimi F;Lauricella C;Zanon C;Perera T;Veronese S;Corti G;Amatu A;Gambacorta M;Diaz LA Jr;Sausen M;Velculescu VE;Comoglio P;Trusolino L;Di Nicolantonio F;Giordano S;Siena S (*Co-First Authors) |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile